Valuation: TScan Therapeutics, Inc.

Market Cap 69.27M 60.56M 55.65M 51.87M 98.39M 6.6B 99.88M 668M 260M 3.24B 260M 254M 11.17B P/E 2026 *
-1.21x
P/E 2027 * -1.15x
Enterprise Value -29.6M -25.87M -23.78M -22.16M -42.04M -2.82B -42.67M -285M -111M -1.39B -111M -109M -4.77B EV / Sales 2026 *
-3.92x
EV / Sales 2027 * -0.7x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-27 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day-0.93%
1 week+26.19%
Current month+8.15%
1 month+8.16%
3 months+4.95%
6 months+3.92%
Current year+6.00%
1 week 0.94
Extreme 0.9434
1.12
1 month 0.83
Extreme 0.8251
1.12
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20Free

Director

67,000 0.1200%
05-20
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%+26.19%-27.89%-57.60% 69.27M
+0.68%+5.92%+80.45%+137.78% 58.73B
+2.32%+5.89%+76.81%+99.20% 53.92B
-10.61%+8.38%-9.90%-9.62% 24.67B
-0.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.47%+46.43%+0.03% 18.8B
-0.29%+9.78%+44.62%-27.94% 17.61B
0.00%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+20.94%+51.67% - 13.9B
Average +2.49%+9.06%+47.30%+124.33% 24.22B
Weighted average by Cap. +2.44%+5.53%+59.76%+138.29%

Financials

2026 *2027 *
Net sales 7.56M 6.61M 6.07M 5.66M 10.73M 720M 10.9M 72.89M 28.34M 354M 28.37M 27.76M 1.22B 7.81M 6.82M 6.27M 5.85M 11.09M 743M 11.26M 75.3M 29.27M 365M 29.3M 28.68M 1.26B
Net income -115M -101M -92.45M -86.17M -163M -10.96B -166M -1.11B -431M -5.39B -432M -423M -18.56B -125M -109M -100M -93.47M -177M -11.88B -180M -1.2B -468M -5.84B -469M -458M -20.13B
Net Debt -98.87M -86.43M -79.43M -74.04M -140M -9.41B -143M -954M -371M -4.63B -371M -363M -15.95B -74.76M -65.35M -60.06M -55.98M -106M -7.12B -108M -721M -280M -3.5B -281M -275M -12.06B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
02/07/26 $1.060 -0.93% 879,505
01/07/26 $1.070 +9.17% 1,680,656
30/06/26 $0.9801 +0.27% 1,045,179
29/06/26 $0.9775 +0.90% 1,263,139
26/06/26 $0.9688 +15.33% 713,271
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.060USD
Average target price
6.000USD
Spread / Average Target
+466.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock